Phyllis Whiteley is an Executive-in Residence at Mohr Davidow and she focuses on building and creating companies in the life sciences.

Most recently she worked with 5AM Ventures where she co-founded Anaphore, Inc. Whiteley has more than 20 years experience across academics, biotech, and pharma in research, development, business, and portfolio management which has led to new regulatory filings and products. She has significant international experience having established affiliates in Japan and Europe. Her work in Pharmacology, Immunology, and Inflammation has resulted in multiple new chemical entities and numerous publications.

Prior to her work in venture capital, Whiteley was an Officer and Senior Vice President, Business Development, Licensing, and Alliance Management at Perlegen Sciences, Inc. Before joining Perlegen, she served as Vice President, Strategic Portfolio Management for F. Hoffman La Roche. During her ten years with Roche she held various positions including Vice President Business Development and Global Licensing Director based in Basel, Switzerland and other research leadership positions including Therapeutic Area Head of Research, Arthritis and Vice President Global Alliances Research, North America. Prior to her Roche tenure, Whiteley held a senior research immunology role with Merck.

Whiteley currently serves on multiple boards including the Personalized Medicine Coalition and Artemis Health.